Cargando…
Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Triple-negative breast cancer constitutes approximately 12%-17% of all breast cancer cases, and >33% of patients develop distant metastases. Systemic cytotoxic chemotherapy is the primary treatment for patients with metastatic triple-negative breast cancer; however, the role of first-...
Autores principales: | Lu, Fei, Hou, Yu, Chen, Zhengting, Jiang, Jie, He, Xi, Xia, Yaoxiong, Cao, Ke, Chang, Li, Li, Wenhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120541/ https://www.ncbi.nlm.nih.gov/pubmed/33977814 http://dx.doi.org/10.1177/15330338211016369 |
Ejemplares similares
-
Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020) -
A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
por: Ge, Long, et al.
Publicado: (2017) -
Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022) -
Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018) -
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis
por: Jin, Zhe, et al.
Publicado: (2020)